SHR-2173

Unknown / undisclosed

Earlyevidence

Evidence outlook

Mid-stage studies underway, no completed readout

Phase 2 studies are registered but none has completed a readout, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 2 (5)
Lupus Nephritis
NCT07229742 · Guangdong Hengrui Pharmaceutical Co., Ltd
2025-11-22 – 2028-03 · Active Lupus Nephritis
What this study did
Other / comorbidity
NCT07299422 · Guangdong Hengrui Pharmaceutical Co., Ltd
2026-04-03 – 2028-11 · Systemic Lupus Erythematosus
What this study did
NCT07354932 · Guangdong Hengrui Pharmaceutical Co., Ltd
2026-03-09 – 2027-12 · Primary IgA Nephropathy
What this study did
NCT07622342 · Guangdong Hengrui Pharmaceutical Co., Ltd
2026-08-28 – 2027-12 · Generalized Myasthenia Gravis
What this study did
NCT07289763 · Guangdong Hengrui Pharmaceutical Co., Ltd
2025-12-31 – 2027-09 · Primary Membranous Nephropathy
What this study did
Phase 1 (4)
Other / comorbidity
NCT07206758 · Guangdong Hengrui Pharmaceutical Co., Ltd
2025-11-12 – 2026-11 · Immune Thrombocytopenia
What this study did
NCT07390747 · Atridia Pty Ltd.
2026-03-06 – 2026-09-28 · Immunology
What this study did
NCT06955598 · Guangdong Hengrui Pharmaceutical Co., Ltd
2024-11-24 – 2025-11-21 · Systemic Lupus Erythematosus
What this study did
NCT06995001 · Guangdong Hengrui Pharmaceutical Co., Ltd
2024-04-28 – 2024-11-28 · Healthy Volunteers
What this study did

Competitive landscape

This drug's own stage for Lupus Nephritis: Phase 2. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
SHR-2173: this drugPhase 2UndisclosedIFNAR1 / TACInot yet gradedNo reviewed efficacy summary in this indication
Belimumab (GSK1550188) (Benlysta)ApprovedMonoclonal antibodyBAFF / BLyS (B-lymphocyte stimulator), BAFF (BLyS)Reliable signalNo reviewed efficacy summary in this indication
ObinutuzumabApprovedMonoclonal antibodyCD20not yet gradedNo reviewed efficacy summary in this indication
Repository Corticotropin (Acthar Gel)ApprovedPeptideMelanocortin receptors (primarily MC2R on the adrenal cortex), Melanocortin 2 receptor (MC2R) (agonist)not yet gradedNo reviewed efficacy summary in this indication
Voclosporin (Lupkynis)ApprovedSmall moleculeCalcineurin, Cyclophilin A (leading to calcineurin inhibition)Reliable signal
NCT03021499: Number of Participants With Adjudicated Renal Response at Week 52 (52 Weeks): Voclosporin — Number of renal responders: 73/179 (40.8%); Number of renal non-responders: 106/179 (59.2%) vs Placebo Oral Capsule — Number of renal responders: 40/178 (22.5%); Number of renal non-responders: 138/178 (77.5%)
Ebribafusp AlfaPhase 2Protein / enzyme therapeuticC3d / Factor Hnot yet gradedNo reviewed efficacy summary in this indication
Rapcabtagene AutoleucelPhase 2UndisclosedCD19not yet gradedNo reviewed efficacy summary in this indication
VonsetamigPhase 1—BCMA x CD3not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(5 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow SHR-2173 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (4)
April 2027 (1)
Phase 2Primary IgA NephropathyRecruiting
Est. primary completion 2027-04 · NCT07354932 · CT.gov ↗
What to watch
June 2027 (1)
Phase 2Lupus NephritisRecruiting
Est. primary completion 2027-06 · NCT07229742 · CT.gov ↗
What to watch
August 2027 (1)
Phase 2Primary Membranous NephropathyRecruiting
Est. primary completion 2027-08 · NCT07289763 · CT.gov ↗
What to watch
September 2027 (1)
Phase 2Generalized Myasthenia GravisRecruiting
Est. primary completion 2027-09 · NCT07622342 · CT.gov ↗
What to watch
2028 (1)
March 2028 (1)
Phase 2Systemic Lupus ErythematosusRecruiting
Est. primary completion 2028-03 · NCT07299422 · CT.gov ↗
What to watch

See the full readout calendar ↗